Effect of cilostazol on the progression of carotid intima-media thickness: A meta-analysis of randomized controlled trials

Atherosclerosis

Volumn 220, Issue 1, 2012, Pages 177-183

  Geng, Deng Feng ^a   Deng, Jing ^a   Jin, Dong Mei ^a   Wu, Wei ^a   Wang, Jing Feng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Carotid intima media thickness; Cilostazol; Diabetes, Type 2; Phosphodiesterase 3 inhibitors; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; CILOSTAZOL; CLOPIDOGREL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ARTERIAL WALL THICKNESS; ARTICLE; BLEEDING; CAROTID ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DISEASE COURSE; DRUG MECHANISM; HEADACHE; HUMAN; LIPID ANALYSIS; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL;

AGED; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PHOSPHODIESTERASE 3 INHIBITORS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRAZOLES; TREATMENT OUTCOME;

EID: 84155166863     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.048     Document Type: Article

References (38)

1. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128(4):262-269.
2. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14-22.
3. Bots M.L., Hoes A.W., Koudstaal P.J., Hofman A., Grobbee D.E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997, 96:1432-1437.
4. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115(4):459-467.
5. Kambayashi J., Liu Y., Sun B., et al. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003, 9(28):2289-2302.
6. Cleanthis M., Bhattacharya V., Smout J., Ashour H., Stansby G. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation. Eur J Vasc Endovasc Surg 2009, 37(5):604-610.
7. Angiolillo D.J., Capranzano P., Ferreiro J.L., et al. Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy. Thromb Haemost 2011, 106(2):253-262.
8. Park S.Y., Shin H.K., Lee J.H., et al. Cilostazol ameliorates metabolic abnormalities with suppression of proinflammatory markers in a db/db mouse model of type 2 diabetes via activation of peroxisome proliferator-activated receptor gamma transcription. J Pharmacol Exp Ther 2009, 329(2):571-579.
9. Lee J.H., Oh G.T., Park S.Y., et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 2005, 313(2):502-509.
10. Suzuki K., Uchida K., Nakanishi N., Hattori Y. Cilostazol activates AMP-activated protein kinase and restores endothelial function in diabetes. Am J Hypertens 2008, 21(4):451-457.
11. Kim M.J., Park K.G., Lee K.M., et al. Cilostazol inhibits vascular smooth muscle cell growth by downregulation of the transcription factor E2F. Hypertension 2005, 45:552-556.
12. Lee K.M., Lee H.J., Kim M.K., et al. Cilostazol inhibits high glucose- and angiotensin II-induced type 1 plasminogen activator inhibitor expression in artery wall and neointimal region after vascular injury. Atherosclerosis 2009, 207(2):391-398.
13. Nakaya K., Ayaori M., Uto-Kondo H., et al. Cilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo. Atherosclerosis 2010, 213(1):135-141.
14. Okutsu R., Yoshikawa T., Nagasawa M., et al. Cilostazol inhibits modified low-density lipoprotein uptake and foam cell formation in mouse peritoneal macrophages. Atherosclerosis 2009, 204(2):405-411.
15. Tamhane U., Meier P., Chetcuti S., et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials. EuroIntervention 2009, 5(3):384-393.
16. Cochrane handbook for systematic reviews of interventions 4.2.5. 2005 update 2005, The Cochrane Collaboration.
17. Katakami N., Kim Y.S., Kawamori R., Yamasaki Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Circulation 2010, 121(23):2584-2591.
18. Mitsuhashi N., Tanaka Y., Kubo S., et al. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Endocr J 2004, 51(6):545-550.
19. Shinoda-Tagawa T., Yamasaki Y., Yoshida S., et al. A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes. Diabetologia 2002, 45(2):188-194.
20. Ahn C.W., Lee H.C., Park S.W., et al. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001, 52(1):45-53.
21. Ahn C.M., Hong S.J., Park J.H., Kim J.S., Lim D.S. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 2010, 26(5):502-510.
22. Rizzo M., Corrado E., Patti A.M., Rini G.B., Mikhailidis D.P. Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?. Expert Opin Pharmacother 2011, 12(4):647-655.
23. Ueno H., Koyama H., Mima Y., et al. Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. J Atheroscler Thromb 2011, [Epub ahead of print].
24. Ikewaki K., Mochizuki K., Iwasaki M., et al. A potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus. Metabolism 2002, 51(10):1348-1354.
25. Thompson P.D., Zimet R., Forbes W.P., Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002, 90(12):1314-1319.
26. Gotoh F., Tohgi H., Hirai S., et al. Cilostazol stroke prevention study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 2000, 9:147-157.
27. Uchiyama S., Demaerschalk B.M., Goto S., et al. Stroke prevention by cilostazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009, 18(6):482-490.
28. Kwon S.U., Cho Y.J., Koo J.S., et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005, 36(4):782-786.
29. Kamal A.K., Naqvi I., Husain M.R., Khealani B.A. Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev 2011, (1):CD008076.
30. Huang Y., Cheng Y., Wu J., et al. Cilostazol versus aspirin for secondary ischaemic stroke prevention cooperation investigators. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008, 7(6):494-499.
31. Shinohara Y., Katayama Y., Uchiyama S., et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomized non-inferiority trial. Lancet Neurol 2010, 9(10):959-968.
32. PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage (PICASSO) (ClinicalTrials.gov Identifier: ). [accessed 06.08.11]. http://clinicaltrials.gov/ct2/show/NCT01013532.
33. Agrawal N.K., Maiti R., Dash D., Pandey B.L. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. Pharmacol Res 2007, 56(2):118-123.
34. Inoue T., Uchida T., Sakuma M., et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 2004, 44(7):1408-1414.
35. Thakore A.H., Guo C.Y., Larson M.G., et al. Association of multiple inflammatory markers with carotid intimal medial thickness and stenosis (from the Framingham Heart Study). Am J Cardiol 2007, 99(11):1598-1602.
36. Lee W.Y., Allison M.A., Kim D.J., Song C.H., Barrett-Connor E. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am J Cardiol 2007, 99(1):99-102.
37. Skoog T., Dichtl W., Boquist S., et al. Plasma tumour necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men. Eur Heart J 2002, 23(5):376-383.
38. Han Y., Li Y., Wang S., et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009, 157(4):733-739.